Does bivalirudin reduce circuit-related thrombotic events and blood product administration compared to heparin in patients requiring venovenous extracorporeal membrane oxygenation?
Bivalirudin may offer a safer and more effective anticoagulation profile than heparin for patients on venovenous ECMO by reducing circuit thrombosis and blood product requirements.
Patients receiving bivalirudin for systemic anticoagulation on venovenous extracorporeal membrane oxygenation experienced a decrease in the number of extracorporeal membrane oxygenation circuit-related thrombotic events as well as a significant decrease in volume of blood products administered.
Rivosecchi et al. (Fri,) studied this question.